Inclusion Criteria:  Subject/subject's legally authorized representative has given Informed Consent according to country regulations, and/or EC requirements Subject is 18 years of age or older Subject has experienced an Acute Ischemic Stroke due to large intracranial vessel occlusion in at least one of the following intracranial vessels: internal carotid artery (ICA), M1 and M2 segments of the middle cerebral artery (MCA), basilar, and vertebral arteries Subject has been or will be treated with a Medtronic market-released neurothrombectomy device as the initial device used to remove the thrombus Subject is willing to participate in a 90-day follow-up visit Treatment within 8 hours of last known well Pre-Stroke Modified Rankin Scale (mRS) score ≤1 (immediately) prior to stroke onset Pre-treatment National Institutes of Health Stroke Scale (NIHSS) ≥ 6 and ≤ 30  Exclusion Criteria:  Concurrent participation in another mechanical neurothrombectomy device trial or any other clinical trial with an active treatment arm or where the study procedure or treatment might confound the study analysis Patients meeting the contraindication as mention in the IFU of devices Patients identified with active COVID-19 infection at the time of enrollment